Registration number: 09054312

Medaco Limited

Contents

Abridged Balance Sheet	1 to 2
Notes to the Unaudited Abridged Financial Statements	3 to 7

Medaco Limited

(Registration number: 09054312)
Abridged Balance Sheet as at 31 December 2025

	Note	2025 £	2024 £
Fixed assets
Intangible assets	4	179,877	224,157
Tangible assets	5	329,108	401,561
		508,985	625,718
Current assets
Stocks		549,625	592,776
Debtors		1,216,959	862,311
Cash at bank and in hand		863,810	584,791
		2,630,394	2,039,878
Creditors: Amounts falling due within one year		(1,082,324)	(879,727)
Net current assets		1,548,070	1,160,151
Total assets less current liabilities		2,057,055	1,785,869
Creditors: Amounts falling due after more than one year		-	(26,835)
Provisions for liabilities		(311,098)	(282,196)
Net assets		1,745,957	1,476,838
Capital and reserves
Called up share capital		100	100
Profit and loss account		1,745,857	1,476,738
Total equity		1,745,957	1,476,838

Medaco Limited

(Registration number: 09054312)
Abridged Balance Sheet as at 31 December 2025

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
	The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

All of the Company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the Board on 7 May 2026 and signed on its behalf by:
 

J P Smallridge

Director

Medaco Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 December 2025

1	General information

The company is a private company limited by share capital, incorporated in England & Wales (Registered number: 09054312).

The address of its registered office is:
Unit 109 Longmead Road
Emerald Park East
Emersons Green
Bristol
BS16 7FG

These financial statements were authorised for issue by the Board on 7 May 2026.

2	Accounting policies

Statement of compliance

These abridged financial statements were prepared in accordance with Financial Reporting Standard 102 Section 1A 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when the amount of revenue can be reliably measured, it is probable the future economic benefits will flow into the entity, and specific criteria have been met for each of the company activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Medaco Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 December 2025

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Plant and machinery	25% reducing balance
Fixtures and fittings	25% reducing balance
Motor vehicles	25% reducing balance

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the Company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Intangible assets

Separately acquired trademarks and licences are shown at historical cost.

Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date.

Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class	Amortisation method and rate
Goodwill	10% straight line

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Provisions

Provisions are recognised when the Company has an obligation at the reporting date as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

Medaco Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 December 2025

Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.

Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the balance sheet as a finance lease obligation.

Lease payments are apportioned between finance costs in the profit and loss account and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

3	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 61 (2024 - 54).

4	Intangible assets

	Total £
Cost or valuation
At 1 January 2025	578,692
At 31 December 2025	578,692
Amortisation
At 1 January 2025	354,535
Amortisation charge	44,280
At 31 December 2025	398,815
Carrying amount
At 31 December 2025	179,877
At 31 December 2024	224,157

Medaco Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 December 2025

5	Tangible assets

	Total £
Cost or valuation
At 1 January 2025	751,923
Additions	39,430
Disposals	(20,000)
At 31 December 2025	771,353
Depreciation
At 1 January 2025	350,362
Charge for the year	105,145
Eliminated on disposal	(13,262)
At 31 December 2025	442,245
Carrying amount
At 31 December 2025	329,108
At 31 December 2024	401,561

6	Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

The total amount of financial commitments not included in the balance sheet is £146,898 (2024 - £78,880).

	2025  £	2024 £
Under 1 year	75,828	32,640
1 - 5 Years	71,070	46,240
	146,898	78,880

7	Related party transactions

Advances to directors

Summary of transactions with other related parties

During the period, shareholders of the parent company went overdrawn on their respective loan accounts. The maximum overdrawn balance during the year was £284,630 (2024 - £196,187). At the year end the amount outstanding from the shareholders was £244,654 (2024 - £187,663). Interest has been charged at commercial rates and the balances are repayable on demand.
 

Medaco Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 December 2025

8	Parent and ultimate parent undertaking

The company's immediate parent is Medaco Holdings Limited, incorporated in England & Wales.